StockData
Anbio Biotechnology logo

Anbio Biotechnology (NNNN) stock

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.65−0.23 (-5.93%)

Close on Nov 17, 2026Market cap $525.20MP/E 24.8Yield –

Anbio Biotechnology r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $201.31K, down 55.7% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$201.31K-55.7%
FY2024Dec 31, 2024$454.23K+237.2%
FY2023Dec 31, 2023$134.70K-32.6%
FY2022Dec 31, 2022$200.00K–

More Anbio Biotechnology figures

See a number that looks wrong?